Ilya Frolov Selected Research

Alphavirus Infections

1/2019	Novel Mutations in nsP2 Abolish Chikungunya Virus-Induced Transcriptional Shutoff and Make the Virus Less Cytopathic without Affecting Its Replication Rates.
12/2018	Sindbis Virus Infection Causes Cell Death by nsP2-Induced Transcriptional Shutoff or by nsP3-Dependent Translational Shutoff.
1/2018	β-d-N4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome.
1/2015	Venezuelan equine encephalitis virus variants lacking transcription inhibitory functions demonstrate highly attenuated phenotype.
8/2012	New PARP gene with an anti-alphavirus function.
5/2011	Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype.
11/2002	Roles of nonstructural protein nsP2 and Alpha/Beta interferons in determining the outcome of Sindbis virus infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ilya Frolov Research Topics

Disease

16	Infections 01/2021 - 08/2005
7	Alphavirus Infections 01/2019 - 11/2002
5	Venezuelan Equine Encephalomyelitis 01/2018 - 09/2007
4	Viremia 01/2020 - 08/2005
2	Arthritis (Polyarthritis) 01/2021 - 09/2008
2	Chikungunya Fever 02/2017 - 07/2011
2	Eastern Equine Encephalomyelitis 03/2013 - 10/2007
1	Meningoencephalitis 01/2020
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 01/2016
1	Type I Syndactyly 01/2016
1	Virus Diseases (Viral Diseases) 02/2013
1	Vector Borne Diseases 07/2011
1	Persistent Infection 10/2010
1	Dengue (Dengue Fever) 01/2008
1	Japanese Encephalitis 01/2008
1	Encephalitis (Encephalitis, Rasmussen) 01/2008
1	Flavivirus Infections 08/2006
1	Diarrhea 03/2005
1	Superinfection 03/2005
1	Glioma (Gliomas) 10/2004
1	Neoplasms (Cancer) 10/2004

Drug/Important Bio-Agent (IBA)

18	VaccinesIBA 01/2021 - 03/2006
8	Proteins (Proteins, Gene)FDA Link 01/2019 - 11/2002
5	Capsid Proteins (Capsid Protein)IBA 01/2020 - 10/2010
5	Antiviral Agents (Antivirals)IBA 01/2016 - 08/2005
3	RNA (Ribonucleic Acid)IBA 07/2014 - 03/2005
3	Glycoproteins (Glycoprotein)IBA 09/2007 - 10/2004
2	AntigensIBA 01/2015 - 02/2013
2	EnzymesIBA 01/2015 - 07/2014
2	Viral RNAIBA 04/2013 - 03/2005
2	InterferonsIBA 05/2012 - 11/2002
1	Ribavirin (Virazole)FDA LinkGeneric 01/2018
1	Complementary DNA (cDNA)IBA 02/2017
1	Pattern Recognition ReceptorsIBA 01/2016
1	ImmunosorbentsIBA 01/2015
1	Viral Structural Proteins (VP(1))IBA 02/2013
1	Attenuated VaccinesIBA 09/2008
1	Interferon-betaIBA 07/2008
1	Neutralizing AntibodiesIBA 10/2007
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 10/2004
1	Laminin ReceptorsIBA 10/2004
1	beta-Galactosidase (Lactaid)IBA 10/2004

Therapy/Procedure

1	Therapeutics 01/2018